The “Drug Value & Market Access Optimization” report has been designed as a working tool to help pharmaceutical companies optimize the valuation of their drugs. This report reviews:
- The economic and healthcare environment
- The R&D cost of drugs
- The drug pricing strategic approaches of pharmaceutical companies, governments and payers
- The market access processes in selected countries (France, Germany, Italy, Spain, UK and USA)
- The best practices in market access
- The ways to leverage the corporate reputation of pharma companies
DESCRIPTION
- Electronic copy: 200 pages (PowerPoint)
- Language: English